Atlas Trials

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Clinical trial NCT02743078 · TERMINATED

Trial details

NCT number
NCT02743078
Sponsor
RTOG Foundation, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
GlioblastomaGliomaGliosarcoma
Start date
2017-05-09
Primary completion
2019-10-15
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.